Neurocrine Biosciences | Los Gastos Financieros De La Deuda



Interest Expense On Debt Cambio Fecha
AbbVie USD 610M 19M 2024-12
Acadia Pharmaceuticals 0 4.12M 2024-09
Agios Pharmaceuticals 3.01M 10.05M 2024-12
ALKERMES USD 0 4.65M 2025-03
Alnylam Pharmaceuticals USD 38.65M 325K 2025-03
Amgen USD 723M 24M 2025-03
Biogen USD 60M 200K 2024-12
BioMarin Pharmaceutical USD 2.86M 286K 2025-03
Cytokinetics USD 22.59M 296K 2024-12
Dynavax Technologies USD 1.7M 5K 2024-12
Exelixis 23.4M 3.9M 2023-09
Gilead Sciences USD 260M 12M 2025-03
Halozyme Therapeutics USD 4.54M 16K 2024-12
Incyte USD 660K 241K 2025-03
Ionis Pharmaceuticals USD 19M 16.41M 2025-03
Neurocrine Biosciences USD 1.1M 0 2024-03
Pfizer USD 654M 85M 2025-03
Prothena 0 0 2024-06
Regeneron Pharmaceuticals USD 8.7M 1.8M 2025-03
Repligen USD 5.25M 212K 2025-03
Sarepta Therapeutics USD 4.92M 86K 2024-09
Teva Pharmaceutical Industries USD 224M 1000K 2024-12
Ultragenyx Pharmaceutical 15.52M 190K 2024-12
Vertex Pharmaceuticals USD 2.8M 4.7M 2024-12



Neurocrine Biosciences Los Gastos Financieros De La Deuda - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.